FLT3LG Specific Neutra™ Antibody Products

Are you struggling with prolonged antibody validation cycles or inconsistent targeting of FLT3LG? Creative Biolabs' FLT3LG specific Neutra™ antibody products leverage advanced epitope mapping and high-affinity engineering to deliver reliable tools for accelerating therapeutic discovery and validating FLT3LG-driven pathways.

Introduction to FLT3LG

Fms-related tyrosine kinase 3 ligand (FLT3LG) is a critical cytokine regulating hematopoietic stem cell proliferation, differentiation, and immune cell homeostasis. As a transmembrane protein, FLT3LG exists in both membrane-bound and soluble forms, binding exclusively to the FLT3 receptor tyrosine kinase to activate downstream signaling cascades. Its role extends across innate and adaptive immunity, making it indispensable for studying immune modulation, cancer biology, and regenerative therapies.

• Structure

FLT3LG is characterized by a conserved four-helix bundle structure typical of type I cytokines. The active ligand forms a homodimer, with each monomer comprising approximately 180 amino acids. Structural studies reveal that dimerization is essential for receptor activation, as the dual-binding interface ensures proper orientation of the FLT3 extracellular domain. Post-translational modifications, including glycosylation at specific asparagine residues, enhance stability and ligand-receptor binding affinity.

• Related Signaling Pathways

FLT3LG binding activates the FLT3 receptor, triggering phosphorylation of downstream effectors such as PI3K/AKT, MAPK/ERK, and STAT5. These pathways drive cellular proliferation, survival, and differentiation. Dysregulation of FLT3LG-FLT3 signaling is implicated in pathological conditions, including leukemogenesis, where constitutive activation promotes unchecked myeloid cell expansion.

Fig.1 FLT3LG-FLT3 signaling.¹

• Associated Pathologies

Aberrant FLT3LG expression or FLT3 receptor mutations are linked to acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and autoimmune disorders. Overactivation of the FLT3 pathway in AML correlates with poor prognosis, while insufficient FLT3LG signaling contributes to immunodeficiency and hematopoietic failure.

Applications of Anti-FLT3LG Neutralizing Antibodies

• Therapeutic Development in Hematologic Malignancies

Neutralizing FLT3LG antibodies are pivotal in AML research, where they suppress FLT3 hyperactivity to inhibit leukemic cell proliferation. Preclinical models demonstrate that antibody-mediated blockade synergizes with chemotherapy, reducing tumor burden and improving survival rates.

• Immunomodulation Research

By disrupting FLT3LG-FLT3 signaling, these antibodies elucidate mechanisms underlying dendritic cell maturation and T-cell activation. This insight supports immunotherapy development, particularly for autoimmune diseases where modulating immune cell differentiation is therapeutic.

• Stem Cell Expansion and Differentiation

FLT3LG-neutralizing antibodies optimize ex vivo expansion of hematopoietic stem cells (HSCs) for transplantation. By temporally controlling FLT3 signaling, researchers enhance HSC yield while maintaining pluripotency, advancing regenerative medicine applications.

• Diagnostic Biomarker Validation

High-specificity anti-FLT3LG antibodies enable quantification of soluble FLT3LG in patient sera, aiding biomarker discovery for early cancer detection and monitoring minimal residual disease in leukemia.

Our Anti-FLT3LG Antibodies

Creative Biolabs' anti-FLT3LG neutralizing antibodies are engineered to block ligand-receptor interaction with sub-nanomolar affinity. These antibodies enable precise inhibition of FLT3LG-driven signaling in vitro and in vivo, facilitating functional studies of hematopoiesis, immune regulation, and leukemia progression. Validated across ELISA, flow cytometry, and bioassays, our antibodies exhibit exceptional specificity, minimizing off-target effects even in complex biological matrices.

Creative Biolabs offers FLT3LG specific Neutra™ antibody products, empowering researchers to tackle complex challenges in oncology, immunology, and regenerative medicine. With rigorously validated performance and tailored support, our tools are designed to accelerate your breakthroughs.

Contact our team today to discuss your project and explore custom solutions.

REFERENCE

1. Zarychta, Julia, et al. "CAR-T cells immunotherapies for the treatment of acute myeloid leukemia—recent advances." Cancers 15.11 (2023): 2944. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers15112944